- ANI Pharmaceuticals (NASDAQ:ANIP +1.4%) acquires exclusive rights to distribute 1% and 2.5% hydrocortisone cream for rectal use and a generic version of Cipher Pharmaceuticals' (CPHR) Lipofen (fenofibrate capsules, 50 mg and 150 mg), from H-2 Pharma, LLC for $10M. The transaction also includes an undisclosed early-stage generic injectable.
- Last year, generic Lipofen generated $21.9M in sales through licensee Kowa Pharmaceuticals America. ANI will earn a royalty of 7.5% of net profits while the product is transitioned to ANI, who will launch it under its own label in Q2.
- The combined market for the hydrocortisone cream is $73M. ANI will launch both strengths in Q2 as well. It will retain a portion of the net profits from all sales.